Cardio Diagnostics Holdings (CDIO) Preferred Stock Liabilities (2021 - 2022)
Cardio Diagnostics Holdings (CDIO) posted Preferred Stock Liabilities of $65.5 million for Q3 2022, up 0.81% sequentially from $65.0 million in Q2 2022.
Cardio Diagnostics Holdings (CDIO) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
Cardio Diagnostics Holdings has reported Preferred Stock Liabilities for 2 years, with the latest figure at $65.5 million in Q3 2022.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $65.5 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $65.5 million (changed N/A YoY) and the FY2021 annual result came in at $65.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $65.5 million in Q3 2022 per CDIO's latest filing, from $65.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $65.5 million in Q3 2022 and troughed at $65.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 65.52 Mn |
| Jun 30, 2022 | 65.00 Mn |
| Mar 31, 2022 | 65.00 Mn |
| Dec 31, 2021 | 65.00 Mn |